Literature DB >> 6231593

[Distribution of constituent beta-lactamases in Pseudomonas aeruginosa].

A Philippon, A Thabaut, M Meyran, P Nevot.   

Abstract

Acquired resistance of Pseudomonas aeruginosa to beta-lactam antibiotics, e.g. ticarcillin, has the following characters: The incidence of ticarcillin-resistant strains is about 21% but it varies with hospitals from 10.9 to 35.1%. Resistance is predominantly due to beta-lactamases, which are produced by two-thirds of the strains (64.4% in 1982, 67.9% in 1983). The presence of beta-lactamase positive strains is dependent upon the type of patient, the hospital unit (e.g. urology or burns) and the nature of the specimen collected. Most beta-lactamase positive strains spontaneously produce one single penicillinase of the CARB (53.8%), OXA (30.5%) or TEM (8.7%) type. New types of beta-lactamases may develop and hydrolyse beta-lactam antibiotics such as ticarcillin, azlocillin, cefoperazone or cefsulodin. With beta-lactam antibiotics (cefotaxime, moxalactam, ceftazidime) that resist hydrolysis, bacterial resistance is due to production of a constitutive beta-lactamase of the cephalosporinase type. This enzyme has recently appeared and its incidence is low (6.8%). Associated beta-lactamases (e.g. penicillinase plus cephalosporinase) are exceptional.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6231593

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  7 in total

1.  Lack of additive effect between mechanisms of resistance to carbapenems and other beta-lactam agents in Pseudomonas aeruginosa.

Authors:  C Dib; J Trias; V Jarlier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

2.  Properties of a novel carbenicillin-hydrolyzing beta-lactamase (CARB-4) specified by an IncP-2 plasmid from Pseudomonas aeruginosa.

Authors:  A M Philippon; G C Paul; A P Thabaut; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

3.  Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.

Authors:  L Gutmann; M D Kitzis; S Yamabe; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

4.  Detection of plasmid-mediated beta-lactamases with DNA probes.

Authors:  S Huovinen; P Huovinén; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

5.  Oligonucleotide probes (TEM-1, OXA-1) versus isoelectric focusing in beta-lactamase characterization of 114 resistant strains.

Authors:  M Ouellette; G C Paul; A M Philippon; P H Roy
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

6.  Molecular hybridization versus isoelectric focusing to determine TEM-type beta-lactamases in gram-negative bacteria.

Authors:  M Jouvenot; M L Deschaseaux; M Royez; C Mougin; R C Cooksey; Y Michel-Briand; G L Adessi
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

7.  Evaluation of plasmid-encoded beta-lactamase resistance in Escherichia coli blood culture isolates.

Authors:  S Huovinen; P Huovinen; K Torniainen; G A Jacoby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-10       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.